LON:BVX BiVictriX Therapeutics (BVX) Share Price, News & Analysis GBX 7.50 0.00 (0.00%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range 7.32▼ 7.5050-Day Range 7.30▼ 1452-Week Range 7▼ 15.30Volume201,500 shsAverage Volume86,281 shsMarket Capitalization£6.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get BiVictriX Therapeutics alerts: Email Address Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About BiVictriX Therapeutics Stock (LON:BVX)BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.Read More BVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BVX Stock News HeadlinesSeptember 3, 2024 | insidertrades.comInsider Buying: BiVictriX Therapeutics Plc (LON:BVX) Insider Acquires 20,000 Shares of StockSeptember 4 at 1:25 AM | americanbankingnews.comInsider Buying: BiVictriX Therapeutics Plc (LON:BVX) Insider Buys 20,000 Shares of StockSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 12, 2024 | msn.comBivictrix quits London’s AIM to chase private funding as market ‘undervalues’ firmAugust 12, 2024 | marketwatch.comBiVictriX Therapeutics Proposes Delisting From London's AIMApril 17, 2024 | investing.comBiVictriX Therapeutics PLC (BVX)February 15, 2024 | finance.yahoo.comWhen Will BiVictriX Therapeutics Plc (LON:BVX) Turn A Profit?December 6, 2023 | proactiveinvestors.comBiVictriX Therapeutics' former chair moves onSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… October 12, 2023 | reuters.comBRIEF-Bivictrix Therapeutics PLC Extended Survival Rates Reported With Bvx001 In A Pre-Clinical Model Of Acute Myeloid LeukaemiaOctober 12, 2023 | proactiveinvestors.comBiVictriX says latest preclincial leukaemia data could accelerate progressOctober 6, 2023 | finance.yahoo.comBiVictriX Therapeutics appoints combined CFO/CBO to boost out-licensing effortsSeptember 20, 2023 | finance.yahoo.comBiVictriX Therapeutics "looking really healthy" after positive first halfSeptember 20, 2023 | finance.yahoo.comBiVictriX Therapeutics to "continue seeking out positive relationships"September 20, 2023 | finance.yahoo.comMarket Sentiment Around Loss-Making BiVictriX Therapeutics Plc (LON:BVX)September 20, 2023 | finance.yahoo.comBiVictriX Therapeutics passes "exciting milestone" with US patent for BVX001September 20, 2023 | finance.yahoo.comWhen Will BiVictriX Therapeutics Plc (LON:BVX) Become Profitable?See More Headlines Receive BVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiVictriX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:BVX CUSIPN/A CIKN/A Webwww.bivictrix.com PhoneN/AFaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-2,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-103.99% Return on Assets-62.99% Debt Debt-to-Equity Ratio8.81 Current Ratio4.40 Quick Ratio7.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 3.40 per share Price / Cash Flow2.20 Book ValueGBX 3 per share Price / Book2.50Miscellaneous Outstanding Shares82,530,000Free FloatN/AMarket Cap£6.19 million OptionableNot Optionable Beta-0.60 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMs. Tiffany Jane Thorn BSc. MSc. (Age 37)M.Sc., CEO & Executive Director Comp: $192.5kDr. Adrian Howd Ph.D. (Age 53)Chief Business Officer & CFO Simon WallworkSecretaryKey CompetitorsOKYO PharmaLON:OKYOOptiBiotix HealthLON:OPTIAorTech InternationalLON:AOROndine BiomedicalLON:OBIOxford BioDynamicsLON:OBDView All CompetitorsInsidersRobert Edward HawkinsBought 20,000 shares on 8/30/2024Total: £140,000.00 ($7.00/share)View All Insider Transactions BVX Stock Analysis - Frequently Asked Questions How have BVX shares performed this year? BiVictriX Therapeutics' stock was trading at GBX 10.50 at the beginning of the year. Since then, BVX shares have decreased by 28.6% and is now trading at GBX 7.50. View the best growth stocks for 2024 here. How do I buy shares of BiVictriX Therapeutics? Shares of BVX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:BVX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiVictriX Therapeutics Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share BiVictriX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.